DekaBank Deutsche Girozentrale
CADX

DekaBank Deutsche Girozentrale’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-48,900
Closed -$449K – 1019
2013
Q4 		$449K Buy
48,900
+1,000
+2% +$7.22K 0.01% 561
2013
Q3 		$302K Buy
+47,900
New +$304K 0.01% 603

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DekaBank Deutsche Girozentrale's CADX Position: Q1 2014 in Review

DekaBank Deutsche Girozentrale sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 48,900 shares — an estimated $449K sold.

DekaBank Deutsche Girozentrale first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $449K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • DekaBank Deutsche Girozentrale reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 48,900 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $449K.
  • DekaBank Deutsche Girozentrale first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • DekaBank Deutsche Girozentrale's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $449K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2014, filed 15 May 2014.